Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for Schering-Plough Corporation
-0.43 (-2.75%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.97 - 15.69
52 week 9.16 - 17.53
Open 15.64
Vol / Avg. 657,291.00/1.40M
Mkt cap 2.09B
P/E     -
Div/yield     -
EPS -0.57
Shares 133.45M
Beta 1.54
Inst. own 108%
Feb 22, 2016
Q4 2015 Nektar Therapeutics Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 19, 2015
Nektar Therapeutics at Jefferies Autumn Global Healthcare Conference - Webcast
Nov 10, 2015
Nektar Therapeutics at Credit Suisse Healthcare Conference
Nov 5, 2015
Q3 2015 Nektar Therapeutics Earnings Call - Webcast
Nov 5, 2015
Q3 2015 Nektar Therapeutics Earnings Release
Oct 8, 2015
Nektar Therapeutics Nektar Therapeutics 2015 R&D Day - Webcast
Sep 9, 2015
Nektar Therapeutics at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -13.68% -26.86%
Operating margin 0.70% -8.21%
EBITD margin - -1.77%
Return on average assets -7.26% -12.31%
Return on average equity -88.74% -
Employees 438 -
CDP Score - -


455 Mission Bay Blvd S
SAN FRANCISCO, CA 94158-2158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
John Nicholson Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Gilbert M. Labrucherie J.D. Senior Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 61
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 63
Bio & Compensation  - Reuters